Gilead has a rich pipeline of promising medicines across multiple indications in Oncology with numerous submissions and readouts planned through 2025 and beyond. There are >15 active pivotal registrational trials, a robust early-mid phase pipeline, and a myriad of partnerships, collaborations, and opt-ins that require strong Clinical Operations leadership of study management teams and global oversight of trial activities including site and contract resource operations (CRO) partnerships.